drugset
drugset / Trial / NCT05614895

A Study to Investigate the Pharmacokinetics of RO7223280 in Critically Ill Participants With Bacterial Infections

NCT05614895 ↗

Phase 1 Completed 48 enrolled Hoffmann-La Roche
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The main aim of the study is to investigate the plasma pharmacokinetics (PK) and safety of intravenous (IV) administration of a single dose of 400 milligrams (mg) or 600 mg RO7223280 in critically ill participants with bacterial infections.

Timeline

Start
2022-12-03
Primary completion
2024-01-13
Completion
2024-01-13

Drugs

EvaluationDrugModalityDoseRoute
Subject ZOSURABALPIN Small molecule 400 mg Intravenous
Subject ZOSURABALPIN Small molecule 600 mg Intravenous

Indications

bacterial infectious disease